StockData

Cellectar Biosciences vs Moleculin Biotech

CLRB and MBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLRB and MBRX compare

Moleculin Biotech is the larger company, worth 15 times as much as Cellectar Biosciences ($133M against $8.7M).

Cellectar Biosciences scores higher on the StockData Score (6 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLRBMBRX
Size and price
Market cap$8.7M$133M
Share price$0.920$6.83
Change, 1 year−68.3%−96.9%
Change, 5 years−99.6%−100.0%
Beta (5Y)1.73−1.10
Employees11150K
StockData Score
Total score6 (better)4
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/B0.3× (better)11.5×
Profitability
Return on equity−124% (better)−524%
Financial health
Debt / equity0.000.00
Current ratio6.66 (better)0.94
Altman Z-score−11.14 (better)−11.19
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.8%0.05%
Held by insiders0.97%20.2%
Insider net buying, 12 months$49.3K–
Short interest, % of float2.3%0.35%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.